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isBackground: H1-receptor antagonists are considered to be
particularly effective in reducing pruritus, and they are
therefore recommended as first-line treatment in patients with
chronic idiopathic urticaria (CIU). Recently, antileukotriene
receptors have been used in patients with CIU, either
administered as monotherapy or combined with H1-receptor
antagonists.
Objective: We compared the clinical efficacy of 5 mg of
desloratadine administered once daily either as monotherapy
or combined with a leukotriene antagonist, 10 mg of
montelukast daily, and 10 mg of montelukast administered
daily as monotherapy for the treatment of patients affected by
CIU with placebo.
Methods: One hundred sixty patients aged 18 to 69 years (mean
6 SD, 43.9 6 13.4 years) with a history of moderate CIU were
selected. A randomized, double-blind, double-dummy, placebo-
controlled, parallel-group study design was used. Patients were
treated with 5 mg of desloratadine once daily (n = 40), 10 mg of
montelukast once daily (n = 40), 5 mg of desloratadine (n = 40)
in the morning plus montelukast in the evening, or matched
placebo (n = 40). Assessment of treatment efficacy was based on
scores of daily cutaneous symptoms evaluated reflectively and
instantaneously.
Results: Only the group treated with desloratadine as
monotherapy or as combined therapy concluded the whole
study. Twenty-seven of the 40 patients in the montelukast group
and 35 of the 40 patients in the placebo group discontinued the
treatment. As reflective evaluation, all groups showed
significant differences compared with the placebo group in
terms of total symptom score, number of hives, and size of
largest hive. In addition to the pruritus, only the groups treated
with desloratadine as monotherapy or combined therapy
showed significant differences compared with those receiving
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doi:10.1016/j.jaci.2004.06.018placebo, whereas there were no differences between the
montelukast and placebo groups. Finally, no differences were
found between the desloratadine group and the desloratadine
plus montelukast group. The instantaneous evaluation
demonstrated similar results regarding the desloratadine group
and the desloratadine plus montelukast group versus the
placebo group, whereas there were no significant differences
between the group treated with montelukast alone and the
placebo group for pruritus and size of largest hive. No
differences were found between the group treated with
desloratadine alone and the desloratadine plus montelukast
group.
Conclusions: The results of this comparative study demonstrate
that desloratadine is highly effective for the treatment of
patients affected by CIU. In addition, the regular combined
therapy of desloratadine plus montelukast does not seem to
offer a substantial advantage with respect to desloratadine as
monotherapy in patients affected by moderate CIU. (J Allergy
Clin Immunol 2004;114:619-25.)
Key words: Chronic idiopathic urticaria, desloratadine, montelu-
kast
Urticarial episodes lasting longer than 6 weeks are
considered chronic.1,2 In many patients the cause of
chronic urticaria (CU) cannot be identified. In such cases
urticaria is defined as chronic idiopathic urticaria (CIU).1,2
The histopathology of CIU and the cutaneous late-phase
reaction to allergen are greatly similar.3 In patients with
CIU, mast cells are activated, and local tissue inflamma-
tion (pruritus and swelling) is due to histamine release and
possibly other mediators, such as leukotrienes. H1-
receptor antagonists are the first-choice treatment for
patients with CIU,1 but unfortunately, some patients do
not benefit from these agents.1,2,4-8 Then the combination
with a second agent is required, especially if H1-blockers
are only partially effective.
In recent years, some reports have claimed a beneficial
effect for leukotriene receptor antagonists (LT-RAs), such
as montelukast and zafirlukast, as well as the 5-lip-
oxygenase inhibitor zileuton, for the treatment of patients
with CU.9-25 The effects of LT-RAs in patients with CIU
have been evaluated mostly in a heterogeneous population
of patients. The majority of the studies reported in the
literature are anecdotal reports, and only a few are619
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isAbbreviations used
ASA: Acetylsalicylic acid
CIU: Chronic idiopathic urticaria
CU: Chronic urticaria
LT-RA: Leukotriene receptor antagonist
NSAID: Nonsteroidal anti-inflammatory drug
TSS: Total symptom score
placebo-controlled studies.19-21,23,24 Among these studies,
4 demonstrated a beneficial effect of LT-RAs,19-21,24
whereas one demonstrated that LT-RAs do not provide
a significant therapeutic benefit in patients with CU.23
Patient selection is very important to investigate the
efficacy of LT-RAs in CIU. Exclusion criteria are all the
forms of CU secondary to any known cause or the forms of
CU reactivated by drugs or food additives.
In this study we compared the clinical efficacy of
desloratadine, a new H1-receptor antagonist, administered
once daily as monotherapy or combined with a leukotriene
antagonist (montelukast). Determining the efficacy of
montelukast as monotherapy for the treatment of patients
affected by CIUwas also an objective of the present study.
METHODS
Patients
We selected 160 adult patients (49male and 111 female patients; age
range, 18-69 years) with CIU from our outpatient clinic at the University
Hospitals in Palermo and Verona. CIU was defined as the presence of
urticarial lesions for more than 6 weeks’ duration in patients with more
than 3 episodes of urticaria aweekwithout any secondary known causes.
The presence of urticarial skin lesions was confirmed clinically. In all
patients we have excluded the presence of positive skin test results to
autologous serum and the appearance of urticaria after the administration
of acetylsalicylic acid (ASA) or nonsteroidal anti-inflammatory drugs
(NSAIDs) or after a challenge with food additives. Patients affected by
physical or allergic urticaria or by urticaria-vasculitis were also excluded
from the study. The other exclusion criteria of the study were the
following: pregnancy, breast-feeding, important systemic or psychiatric
disease, and habitual use of corticosteroids or LT-RAs for 2 months
before entry into the study or use of oral corticosteroids in the month
before the beginning of the study. Before the study began, approval was
obtained from the ethics committees of the 2 centers involved. Written
informed consent was obtained from all enrolled patients.
Study design
A randomized, double-blind, double-dummy, placebo-controlled,
parallel-group study design was used. In each center patients received
the following treatments: (1) 5 mg of desloratadine daily in the
morning plus placebo of montelukast in the evening; (2) 5 mg of
desloratadine daily in the morning plus 10 mg of montelukast in the
evening; (3) placebo of desloratadine in the morning plus 10 mg of
montelukast 1 day in the evening; or (4) placebo of desloratadine in
the morning plus placebo of montelukast in the evening.
The pharmacist of the University Hospital of Verona prepared
a specific set with the treatments to be used for the study. The
investigators and patients were blinded with respect to the contents
of each set. The pharmacist used commercially available tablets ofdesloratadine (Aerius; Schering-Plough, Italy), montelukast
(Singulair; Merck Sharp and Dohme, Italy), or placebo. All treat-
ments were administered by a person unaware of who was
participating in the study. Rescue medication included loratadine
tablets (Clarytin, 10 mg; Shering-Plough, Italy). No other medication
for urticaria was permitted during the trial.
The treatment period started after the clinical diagnosis of CIU (see
below), without any run-in period. Patients were treated for 6 weeks.
Each patient attended the clinic on 4 different occasions after the
diagnostic procedure. These included an initial clinic visit (visit 1),
a second visit after 3 weeks of treatment (visit 2), a final visit after 6
weeks of treatment (visit 3), and a visit 2 weeks after the end of the
treatment period (follow-up, visit 4).
At visit 1, symptom scores of urticaria were assessed by patients
by means of a visual analog scale (0-9). Enrolled patients received
a daily record diary for cutaneous symptoms. The study was
conducted during 2002. All groups for each treatment included 40
patients: 20 patients (for each treatment) enrolled in Palermo and 20
patients (for each treatment) enrolled in Verona.
Before the beginning of the treatment period, a clinical history was
recorded for each patient, and physical examinations and standard and
specific laboratory investigations for urticaria were also performed. In
particular, the following tests were performed: skin prick test for
common aeroallergens and food allergens26; hematologic parameter
assessment (hemoglobin, red blood cell, platelet, and white blood cell
counts); biochemical assessment (serum electrolytes [sodium and
potassium]); indices of renal function (creatinine, urea, and urine
analysis) and hepatic function (alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, and g-glutamil-trans-
peptidase); glucose-fasting testing; and C-reactive protein, serum
total IgE, and antinuclear and antithyroid antibody measurement.
Finally, in all patients we performed an intradermal test with auto-
logous serum2 and double-blind placebo-controlled challenges with
ASA, NSAIDs, and food additives, as previously described.19,26,27
Efficacy assessments
Throughout the study, disease activity was assessed by the
patients with a scoring system for CIU on the basis of specific signs
and symptoms.28 Patients recorded the scores on their diary cards.
Instruction on how to perform the assessment was provided at the
time of screening. CIU signs and symptom scores were evaluated by
using 4-point scales (0-3) for pruritus, number of hives, size of largest
hive, interference with sleep, and interference with daily activities
(Table I).28 Twice daily (morning and evening) patients scored
pruritus, number of hives, and size of largest hive over the preceding
12 hours (reflective) and immediately at the time of assessment
(instantaneous). These assessments were performed on awakening
(before dosing) and 12 hours later. Reflective assessments of
interference with sleep and daily activities were scored in the
morning and in the evening only, respectively.
Safety assessments
Vital signs were recorded at all visits, whereas electrocardiogra-
phy and laboratory tests were performed at screening and visit 3. All
adverse events were recorded and graded for severity and potential
relation to the medications used in the study.
Safety evaluations included the incidence of treatment-induced or
emergency adverse events, discontinuations because of adverse
events, and changes from baseline in vital signs, laboratory
parameters, and electrocardiographic intervals.
Statistical analysis
The primary assessment of efficacy was based on the differences
between each treatment group versus placebo for total symptom score
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Score Pruritus No. of hives Size of largest hive (cm)
Interference with
sleep
Interference with
daily activities
0 None None None None None
1 Mild, minimal
awareness, easily tolerated
1-6 <1.25 Mild, not troublesome,
adequate sleep
Mild, not troublesome,
little effect on activity
2 Moderate, definite awareness,
bothersome but tolerable
7-12 1.25-2.5 Moderate, awoke
occasionally, average sleep
Moderate, some interference
with activity
3 Severe, difficult to tolerate >12 >2.5 Severe, substantial interference
with sleep, poor sleep
Severe, daily activities
substantially or completely
curtailed
TABLE II. Characteristics of patients
Desloratadine Montelukast Desloratadine plus montelukast Placebo P value
No. 40 40 40 40
Age (y), mean (minimum and maximum) 44.0 (18-63) 44.4 (18-64) 43.7 (20-69) 43.6 (20-65) NS
Sex (M/F) 13/27 12/28 13/27 11/29 NS
Onset of urticaria (mo) 16.6 (6-43) 16.3 (7-34) 16.9 (10-42) 17.0 (7-44) NS
Symptoms,mean (minimum and maximum) 6.4 (5-9) 6.9 (4-9) 6.3 (5-9) 7.1 (4-9) NS
NS, Not significant.Fo
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is(TSS) and for every symptom of the urticaria. The secondary
assessment was based on the differences between the group treated
with desloratadine and the group treated with desloratadine plus
montelukast. Data are presented as means and 95% CIs of the means
of individual score. Adjusted values were subsequently averaged by
patient over the entire observation period. Averages by patient were
examined by using a mixed-effects ANOVA model, with the
treatments (as fixed effect) and the centers (as random effect) as the
main values. F values were calculated by using the mean squares of
the interaction ‘‘centers3 treatments’’ as the error term. Differences
between means were performed by using the Bonferroni multiple
range test (set at 95% CI). Power analysis on post hoc comparisons
was performed with the GPower software package.29 Comparisons
are only denoted as being significant (P< .05, 2 tail) or not significant
if our sample size exceeded the minimum sample size resulting from
a power analysis at a b value of .80
RESULTS
One hundred sixty patients were randomized to treat-
ments, with 40 patients for each treatment (see above). The
baseline characteristics with respect to duration of urticaria
and age of patients are reported in Table II. Only the group
treated with desloratadine as monotherapy or combined
therapy concluded the whole study. Twenty-seven of forty
patients in the montelukast group and 35 of 40 patients in
the placebo group discontinued the treatment.
Assessment of efficacy
Fig 1 andTable III showTSS, pruritus, number of hives,
and size of largest hive in reflective and instantaneous
evaluations. Fig 2 and Table IV show interference with
daily activities and interference with sleep, respectively.
Data are reported as means and 95% CIs of the means of
individual scores during the treatment period and asthe mean difference (95 %CI for difference) between the
treatments.
Reflective evaluation. All groups showed significant
differences compared with placebo in terms of TSS,
number of hives, and size of largest hive. In addition to
the pruritus, only the groups treated with desloratadine as
monotherapy or combined therapy showed significant
differences compared with those receiving placebo, but
there were no differences between the groups treated with
montelukast and placebo.
Comparing the group treated with desloratadine alone
and the group treated with montelukast alone, we found
significant differences for TSS, pruritus, number of hives,
and size of largest hive (P < .001, P < .001, P = .017, and
P = .003, respectively). The comparisons between the
groups treated with desloratadine plus montelukast and
the group treated with montelukast alone showed signif-
icant difference for TSS, pruritus, number of hives, and
size of largest hive (P < .001, P < .001, P = .01, and
P = .003, respectively).
No differences were found between the group treated
with desloratadine alone and the group treated with
desloratadine plus montelukast.
Instantaneous evaluation. The results of the analysis
of the instantaneous evaluation regarding TSS, pruritus,
number of hives, and size of largest hive are similar to the
results of reflective evaluation. Examining the group
treated with montelukast alone versus the group treated
with placebo, we found no difference for pruritus and size
of largest hive, whereas there were significant differences
for TSS (P = .005) and number of hives (P = .001).
In the group treated with desloratadine alone, we found
significant differences for TSS (P < .001), pruritus
(P = .003), number of hives (P = .002), and size of largest
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isTABLE III. Values for desloratadine, montelukast, desloratadine plus montelukast, and placebo and mean differences
between the treatments for TSS (out of 9) pruritus (out of 3), number of hives (out of 3), size of hives (out of 3)
Treatments TSS Pruritus Number of hives Size of hives
Subjective symptoms of urticaria (reflective evaluation), mean (95% CI)
DSL 1.49 (1.44-1.53) 0.50 (0.48-0.51) 0.40 (0.38-0.43) 0.41 (0.39-0.44)
MSK 2.65 (2.54-2.76) 1.20 (1.17-1.23) 0.62 (0.57-0.67) 0.66 (0.61-0.71)
DSL plus MSK 1.50 (1.44-1.57) 0.51 (0.49-0.53) 0.40 (0.38-0.44) 0.42 (0.40-0.44)
PLA 3.26 (3.17-3.36) 1.19 (1.15-1.22) 1.02 (0.97-1.07) 0.88 (0.84-0.93)
Comparisons: mean differences between the treatments (95% CI for difference); reflective evaluation
DSL vs PLA 21.77 (21.89 to 21.66),
P < .001
20.68 (20.72 to 20.65),
P < .001
20.61 (20.67 to 20.56),
P = .001
20.46 (20.52 to 20.41),
P = .001
MSK vs PLA 20.61 (20.72 to 20.49),
P < .001
0.01 (20.02 to 0.05),
P = NS
20.40 (20.45 to 20.34),
P = .001
20.22 (20.28 to 20.17),
P = .003
DSL plus MSK vs PLA 21.76 (21.87 to 1.64),
P < .001
20.67 (20.71 to 20.63),
P < .001
20.61 (20.67 to 20.56),
P = .001
20.46 (20.51 to 20.42),
P < .001
DSL vs MSK 21.66 (21.28 to 21.05),
P < .001
20.70 (20.74 to 20.66),
P < .001
20.21 (20.27 to 20.16),
P = .017
20.24 (20.29 to 20.19),
P = .003
MSK vs DSL plus MSK 1.14 (1.03 to 1.26),
P < .001
0.69 (0.65 to 0.63),
P < .001
0.22 (0.16 to 0.30),
P = .01
0.24 (0.18 to 0.29),
P = .003
DSL vs DSL plus MSK 20.01 (20.13 to 0.09),
P = NS
20.01 (20.05 to 20.02),
P = NS
20.0007 (20.05 to 0.05),
P = NS
20.0001 (20.05 to 0.05),
P = NS
Subjective symptoms of urticaria (instantaneous evaluation), mean (95% CI)
DSL 1.81 (1.77-1.85) 0.45 (0.43-0.48) 0.54 (0.52-0.56) 0.67 (0.65-0.70)
MSK 2.86 (2.78-2.94) 1.02 (0.99-1.06) 0.77 (0.73-0.81) 0.93 (0.90-0.96)
DSL plus MSK 1.75 (1.70-1.80) 0.52 (0.50-0.55) 0.50 (0.47-0.53) 0.63 (0.61-0.66)
PLA 3.41 (3.32-3.49) 1.17 (1.11-1.23) 1.14 (1.11-1.84) 0.95 (0.90-1.01)
Comparisons: mean differences between the treatments (95% CI for difference); instantaneous evaluation
DSL vs PLA 21.59 (21.68 to 21.50),
P < .001
20.71 (20.76 to 20.66),
P = .002
20.60 (20.64 to 20.56),
P < .001
20.27 (20.32 to 20.22),
P = .008
MSK vs PLA 20.54 (20.63 to 20.45),
P = .005
20.14 (20.19 to 0.01),
P = NS
20.37 (20.41 to 20.32),
P = .001
20.02 (20.07 to 0.02),
P = NS
DSL plus MSK vs PLA 21.65 (21.74 to 1.56),
P < .001
20.64 (20.69 to 20.59),
P = .002
20.64 (20.68 to 20.60),
P < .001
20.32 (20.36 to 20.27),
P < .001
DSL vs MSK 21.04 (21.14 to 20.95),
P = .001
20.57 (20.62 to 20.51),
P = .003
20.23 (20.27 to 20.18),
P = .002
20.25 (20.29 to 20.20),
P = .008
MSK vs DSL plus MSK 1.10 (1.01 to 1.20),
P = .001
0.50 (0.45 to 0.55),
P = .004
0.27 (0.22 to 0.31),
P = .001
0.29 (0.24 to 0.34),
P = .007
DSL vs DSL plus MSK 0.05 (20.03 to 0.15),
P = NS
20.006 (20.11 to 0.01),
P = NS
0.004 (20.03 to 0.08),
P = NS
0.04 (20.004 to 0.09),
P = NS
DSL, Desloratadine; MSK, montelukast; PLA, placebo; NS, not significant.
TABLE IV. Mean values for desloratadine, montelukast, desloratadine plus montelukast, and placebo and mean
differences between the treatments for interference with sleep (out of 3) and interference with daily activities
(out of 3)
Treatments Interference with sleep (95% CI) Interference with daily activities (95% CI)
DSL 0.60 (0.58-0.62) 0.35 (0.33-0.37)
MSK 1.00 (0.97-1.03) 0.41 (0.37-0.44)
DSL plus MSK 9.72 (0.69-0.75) 0.40 (0.38-0.42)
PLA 1.03 (0.99-1.07) 0.87 (0.84-0.90)
Comparisons: mean differences between the treatments (95% CI for difference)
DSL vs PLA 20.43 (20.47 to 20.39), P = .003 20.52 (20.55 to 20.48), P = .001
MSK vs PLA 20.03 (20.07 to 0.01), P = NS 20.46 (20.50 to 20.43), P = .002
DSL plus MSK vs PLA 20.31 (20.35 to 20.27), P = .007 20.47 (20.50 to 20.44), P = .002
DSL vs MSK 20.40 (20.44 to 20.35), P = .003 20.06 (20.09 to 20.02), P = NS
MSK vs DSL plus MSK 0.28 (0.24 to 0.32), P = .01 0.0002 (20.03 to 0.03), P = NS
DSL vs DSL plus MSK 20.11 (20.16 to 20.07), P = NS 20.05 (20.08 to 20.01), P = NS
DSL, Desloratadine; MSK, montelukast; PLA, placebo; NS, Not significant.
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isFIG 1. Subjective symptoms of urticaria, TSS, pruritus, numbers of hives, and size of largest hive as reflective
and instantaneous evaluations. Data are reported as means with 95% CIs of the mean of individual scores
during the treatment period. The comparison between treatments is reported in Table III.
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isFIG 2. Interference with sleep and interference with daily activities. Data are reported asmeans with 95% CIs of
the mean of the individual scores during the treatment period. The comparison between treatments is
reported in Table IV.hive (P = .008) in comparison with the group treated with
montelukast alone. We obtained similar results comparing
the group treated with desloratadine plus montelukast
and the group treated with montelukast alone for TSS
(P = .001), pruritus (P = .004), number of hives (P = .001),
and size of largest hive (P = .007).We found no significant
differences between the group treated with desloratadine
alone and the group treated with desloratadine plus
montelukast.
Interference with sleep. Regarding interference with
sleep, significant differences were found between the
groups treated with desloratadine, both as monotherapy
and as combined therapy with montelukast, in comparison
with the placebo group (P = .003 and P = .007, respec-
tively). Comparing the group treated with desloratadine
alone versus the group treated with montelukast alone, we
found significant differences (P = .003). Also, significant
differences were found comparing those treated with
montelukast alone versus those treated with desloratadine
plus montelukast (P = .01). In addition, no differences
were found between the group treated with montelukast
alone versus the group treated with placebo and between
the group treated with desloratadine alone versus the
group treated with desloratadine plus montelukast.
Interference with daily activities. Considering daily
activities, we found significant differences between all
active treatments and the placebo group. We found no
differences among the groups treated with desloratadine
alone, montelukast alone, and desloratadine plus monte-
lukast.
Use of rescue medication. The use of rescue medica-
tion, expressed as the median number of days without the
use of loratadine tablets, was significantly lower in the
groups treated with desloratadine as monotherapy (90.6
days) or combined therapy (91.0 days) than in the
montelukast-treated group (45.2 days, P < .001) or the
placebo-treated group (54.0 days, P < .001). We found no
differences between the group treated with desloratadine
and the group treated with desloratadine plus montelukastand between the group treated with montelukast and the
group treated with placebo.
Safety
A low incidence of adverse events was observed in the
study. All adverse events were rated as mild. Exacerbation
of urticarial symptoms was reported in 27 patients in the
group treated with montelukast and in 35 patients in the
group treated with placebo.
DISCUSSION
The results of this study demonstrate that desloratadine
administered once daily is more effective than montelu-
kast for the treatment of urticarial symptoms in patients
with moderate CIU. The combination of desloratadine
with montelukast failed to produce a substantial advantage
for urticarial symptoms in comparison with desloratadine
administered in monotherapy. Moreover, treatment with
montelukast as monotherapy failed to control the urticarial
symptoms, such as pruritus, in our study in patients
affected by CIU.
In this study we evaluated only patients affected by
moderate CIU. We excluded patients with positive
challenge results to ASA, NSAIDs, or food additive;
those with positive cutaneous test results to autologous
serum; or both.We also excluded patients who reported an
aggravation of their symptoms through pressure.
Therefore the absence of these triggers indicates the
presence of an idiopathic form of urticaria. Angioedema
was rarely present in this group of patients. This is an
important difference compared with some of the previous
reports, in which patients were selected without precise
characteristics.20,21,23
In patients with moderate CIU, the role of leukotrienes
is probably rather insignificant.24 In a previous study we
examined patients with CIU andwith CUwho hadASA or
food additive sensitivity, determining urinary metabolite
concentrations of both histamine and leukotrienes.30 The 2
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isgroups of patients affected by CU had markedly increased
urinary concentrations of methylhistamine at baseline,
thus allowing a clear distinction from the control group
(healthy volunteers). On the contrary, when we compared
urinary leukotriene E4 levels in the same subjects, we
found no difference at baseline in the 3 groups but an
increase in leukotriene levels after challenge only in
patients with ASA or food additive sensitivity. These
results might also explain the low clinical response to
therapy with LT-RAs in patients with CIU with no well-
defined triggers. Recently, the results of the study by
Bagenstose et al24 would confirm that the treatment of
combined therapy with H1-receptor antagonists and LT-
RAs is effective only in patients with autoimmune and
more severe urticaria (positive skin test response to
autologous serum).24,31
Finally, we should consider the economic aspect of the
treatments: the cost of an anti-H1-receptor treatment is
0.53V per day, whereas the daily cost of an antileukotriene
receptor treatment is 2.02V per day. Particularly, the
consumption of rescuemedication (loratadine) is similar in
patients treated with montelukast as monotherapy and in
patients treated with placebo, and these data confirm that
histamine is the most important mediator of the CIU.
In conclusion, the results of this comparative study
demonstrate that desloratadine, regularly administered
once daily, is effective for the treatment of urticarial
symptoms, confirming the results of other studies.28,32
Statistical advice was kindly provided by Full Professor Antonio
Motisi (Dipartimento di Coltivazioni Arboree, Universita` di
Palermo).
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